TC
GYRE icon

TFS Capital’s Gyre Therapeutics GYRE Stock Holding History

TFS Capital’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-42
Closed -$87K – 1019
2014
Q4 		$87K Sell
42
-419
-91% -$807K 0.01% 922
2014
Q3 		$919K Sell
461
-480
-51% -$1.19M 0.08% 400
2014
Q2 		$3.34M Buy
941
+564
+150% +$1.84M 0.26% 84
2014
Q1 		$1.41M Buy
377
+181
+92% +$670K 0.09% 335
2013
Q4 		$641K Buy
196
+42
+27% +$166K 0.03% 720
2013
Q3 		$643K Buy
+154
New +$620K 0.03% 758

Other funds holding GYRE

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

TFS Capital's GYRE Position: Q1 2015 in Review

TFS Capital sold out of Gyre Therapeutics (GYRE) in Q1 2015, closing a stake of 42 shares — an estimated $87K sold.

TFS Capital first reported a position in GYRE in Q3 2013 and held it in 6 quarters. The position peaked at $3.34M in Q2 2014. 49 funds tracked by Wall St. Rank hold GYRE as of Q1 2015.

  • TFS Capital reported no remaining Gyre Therapeutics position as of Q1 2015 after selling out during the quarter.
  • TFS Capital sold 42 Gyre Therapeutics shares in Q1 2015, an estimated $87K.
  • TFS Capital first reported a position in Gyre Therapeutics in Q3 2013 and held it in 6 quarters.
  • TFS Capital's Gyre Therapeutics position peaked at $3.34M in Q2 2014.
  • 49 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q1 2015.

Based on TFS Capital's 13F filing for Q1 2015, filed 29 Apr 2015.